EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prediction of differentiation levels in lung adenocarcinoma using peripheral blood inflammatory cytokines and tumor markers

Yang Li, Jiahuan Wu, Meiling Long, Tingting Zeng, Depeng Jiang iD

PLOS One · 2026

DOI: 10.1371/journal.pone.0339414 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Yang Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, The Second affiliated Hospital of Chongqing Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Lung Neoplasms, Adenocarcinoma of Lung, Cytokines. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Lung Adenocarcinoma (LUAD) has highly aggressive and lethal, and its degree of differentiation significantly influences prognosis and treatment strategies, yet accurate prediction remains challenging. To assess the predictive value of combining peripheral blood inflammatory markers, such as the aggregate index of systemic inflammation (AISI), with tumor markers, including Carcinoembryonic Antigen (CEA) and Cytokeratin 19 fragment antigen 21−1(CYFRA21−1), etc, for determining LUAD differentiation levels.

Methods

This retrospective study included 203 LUAD patients treated at Chongqing Medical University’s Second Affiliated Hospital, categorized by low and high differentiation. Demographic, clinical, and laboratory data including peripheral blood inflammatory and tumor markers were analyzed. A multivariate logistic regression model evaluated these markers’ predictive accuracy.

Results

AISI (OR = 1.64, 95% CI = 1.08–2.58, p = 0.024), CEA (OR = 1.02, 95% CI = 1.00–1.04, p = 0.0497), ferritin (OR = 1.01, 95% CI = 1.00–1.01, p = 0.010), and Progastrin Releasing Peptide (ProGRP) (OR = 1.03, 95% CI = 1.00–1.07, p = 0.047) were risk factors of low differentiation LUAD. The model achieved an Area Under Curve(AUC) of 0.795 (95%CI: 0.726–0.864) for distinguishing low from high differentiation, with decision curve analysis confirming clinical utility.

Conclusion

This model, combining inflammatory and tumor markers, effectively predicts LUAD differentiation, aiding personalized treatment planning, enhancing therapeutic outcomes, and supporting early LUAD detection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorLung NeoplasmsAdenocarcinoma of LungCytokinesAdenocarcinomaHumansFemaleMaleMiddle AgedRetrospective StudiesAgedCarcinoembryonic AntigenPrognosisKeratin-19Cell DifferentiationInflammationROC Curve

Substanzen

Biomarkers, TumorCytokinesCarcinoembryonic AntigenKeratin-19

Autor:innen und Institutionen

  • Department of Respiratory Medicine, The Second affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Department of Endocrinology, The Second affiliated Hospital of Chongqing Medical University, Chongqing, China.

ORCID-Profile: Depeng Jiang

Zitieren

APA

Li, Y., Wu, J., Long, M., Zeng, T., & Jiang, D. (2026). Prediction of differentiation levels in lung adenocarcinoma using peripheral blood inflammatory cytokines and tumor markers. PLOS One. https://doi.org/10.1371/journal.pone.0339414

Vancouver

Li Y, Wu J, Long M, Zeng T, Jiang D. Prediction of differentiation levels in lung adenocarcinoma using peripheral blood inflammatory cytokines and tumor markers. PLOS One. 2026. doi:10.1371/journal.pone.0339414

BibTeX
@article{Li2026,
  author = {Li, Yang and Wu, Jiahuan and Long, Meiling and Zeng, Tingting and Jiang, Depeng},
  title = {Prediction of differentiation levels in lung adenocarcinoma using peripheral blood inflammatory cytokines and tumor markers},
  journal = {PLOS One},
  year = {2026},
  doi = {10.1371/journal.pone.0339414}
}
Kostenlos starten →